Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes)

Waelti, Ernst R.; Glück, Reinhard

doi:10.1002/(sici)1097-0215(19980831)77:5<728::aid-ijc11>3.0.co;2-y

Cited by 53 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study we investigated the efficacy of a mumps DNA vaccine intranasally delivered by virosomes and administered to mice. Virosomes comprising cationic lipids and fusion active influenza hemagglutinin protein appear to be a very efficient delivery system for nucleic acid vaccines (Cryz and Glück, 1998;Waelti and Glück, 1998). The use of DNA vaccines associated with virosomes avoids the complex physicochemical problems associated with the use of adjuvants and may also result in in vivo antigen presentation of the encoded epitopes in a manner similar to the presentation of the epitope that would occur following natural infection.…”

Section: Introductionmentioning

confidence: 99%

Intranasal Immunization with Mumps Virus DNA Vaccine Delivered by Influenza Virosomes Elicits Mucosal and Systemic Immunity

et al. 2000

Self Cite

View full text Add to dashboard Cite

To improve the efficiency of liposome-mediated DNA transfer as a tool for gene therapy or vaccinology, we have further developed a new delivery system based on the modified immunopotentiating reconstituted influenza virus (IRIV). In this study, we engineered a plasmid DNA vector expressing the mumps virus hemagglutinin or the fusion protein. The administration of this DNA vaccine delivered by influenza virosomes, in combination with the mucosal adjuvant Escheriagen via the intranasal route, was efficient for inducing an immune response, both mucosally and systemically, in mice. The production of IgG2a mumps virus-specific antibodies and the secretion of interleukin 10 (IL-10) by antigen-specific T cells indicated that not only Th1 but also Th2 responses were induced by this DNA vaccine formulation. These results suggest that cationic virosomes in combination with Escheriagen may have great potential as an efficient delivery system for intranasal DNA immunization and provide an immune barrier at the mucosal sites.

show abstract

Section: Introductionmentioning

confidence: 99%

Intranasal Immunization with Mumps Virus DNA Vaccine Delivered by Influenza Virosomes Elicits Mucosal and Systemic Immunity

et al. 2000

Self Cite

View full text Add to dashboard Cite

show abstract

“…Antisence-L-mycvirosomes were added to the cells of human small cell lung cancer cell lines that expressed led to strong inhibition of thymidine incorporation in a concentration-dependent manner. Virosomesentrapped sense L-myc OPT and random-order OPT had only minimal effects on the thymidine uptake 30 .…”

Section: Proteins Also Can Be Delivered To Cells Via Virosomementioning

confidence: 93%

Untitled

2012

IJPSR

View full text Add to dashboard Cite

Vaccine development has continuously shifted away from live attenuated or inactivated whole organisms. Although this approach having good efficacy but for improvement on comparison of risk/benefit ratio which needs improvement due to their highly complex compositions which result in safety concerns. As a consequence, a number of indications remained unadressed. The next generation vaccines represented as subunit vaccines, whereby the only pathogens fragments used which are relevant in inducing protective immunity. For the successful subunit vaccination two major key requirements are safe carrier and adjuvant system, since the small, isolated pathogen fragments themselves are generally weak immunogens. Pevion's virus-like particle (VLP) vaccine technology, called virosomes, and their design is specifically for the development of safe and effective subunit vaccines. Virosomes based vaccination has already been approved in more than 40 countries, including for elderly and infants. It is successful in solid regulatory & safety track record as well as the feasibility of production upscaling. The outstanding profile with combined efficacy and safety of virosomes-based vaccines are known for its origin in the unique mode of action of these multifunctional particles. It leads to a comprehensive induction of a complete immune response, in contrast to single-sided triggers. Virosomes are reconstituted viral envelopes that can serve as vaccines and as vehicles for cellular delivery of macromolecules.The prospect of drug delivery and targeting using virosomes is an interesting field of research and development. As virosomes are biocompatible, biodegradable, nontoxic, and non-autoimmunogenic, and various attempts have been made to use them as vaccines or adjuvants as well as delivery system for drugs, nuleic acids, nucleic acids, or genes for therapeutic purposes. The virus of choice is influenza virus. Virosomal drug delivery depends on the methods used to prepare the encapsulated bioactive material their incorporation into the virosomes, and followed by the characterization and formulation of the finished preparations. This technology can potentially be used to deliver peptides, nucleic acids or genes, and drugs like antibiotics, anticancer agents, and steroids. In this paper reviewed about the advantages of virosomes in successful delivery of immunogens.

show abstract

“…This has been accomplished using the vitamin folate conjugated onto liposomes through a polyethylene spacer to target folate receptorbearing cells (Wang et al, 1995). Transferrin (Cheng, 1996), viral glycoproteins (Waelti and Gluck, 1998), and monoclonal antibodies (Compagnon et al, 1997) have also been used to enhance liposome gene delivery. Upon cellular binding and internalization, targeted liposomes have been found in endosomal compartments, as have their nontargeted counterparts (Lippalalainen et al 1997;Zabner et al, 1995).…”

Section: Synthetic Vectorsmentioning

confidence: 99%

Receptor-mediated targeting of gene delivery vectors: Insights from molecular mechanisms for improved vehicle design

Varga

Wickham

Lauffenburger

2000

Biotechnol. Bioeng.

110

View full text Add to dashboard Cite

One way to deliver transgenes to cells in a selective manner is to target the delivery vehicles, or vectors, to specific cell‐surface receptors as a first step toward ulimate transport of the gene to the nucleus for expression. While selective delivery, although often to undesired cell types, occurs naturally for some viral vectors and can be achieved for nonviral vehicles, current understanding and control of the delivery mechanism is inadequate for many therapeutic applications. The complicated nature of receptor‐mediated transgene uptake and transport requires improved analysis to more effectively evaluate delivery vehicles. As receptor‐mediated pathways for gene delivery typically involve vector binding, internalization, subcellular trafficking, vesicular escape, nuclear translocation, and unpackaging for transcription, each of these processes offer mechanisms that can be exploited to enhance targeted gene delivery via properly designed vehicles. For the purpose of this review, current targeted gene delivery vehicles are divided into three approaches: viral, synthetic, and hybrid vectors. Each approach possesses advantages as well as disadvantages at the present time for in vitro and in vivo application, and provides particular challenges to overcome in order to gain significantly improved targeted delivery properties. Quantitative experiments and mathematical modeling of the gene delivery pathway will serve to provide insight into molecular mechanisms and rate‐limiting steps for effective gene expression. Information on molecular mechanisms obtained by such methodologies can then be applied to specific vectors, whether viral, synthetic, or hybrid, allowing for the creation of targeted, effective, and safe gene therapeutics. © 2000 John Wiley & Sons, Inc. Biotechnol Bioeng 70: 593–605, 2000.

show abstract

Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes)

Cited by 53 publications

References 17 publications

Intranasal Immunization with Mumps Virus DNA Vaccine Delivered by Influenza Virosomes Elicits Mucosal and Systemic Immunity

Intranasal Immunization with Mumps Virus DNA Vaccine Delivered by Influenza Virosomes Elicits Mucosal and Systemic Immunity

Untitled

Receptor-mediated targeting of gene delivery vectors: Insights from molecular mechanisms for improved vehicle design

Contact Info

Product

Resources

About